At the annual American Diabetes Association meeting, Bristol-Myers Squibb unveiled positive results from a Phase IIa study of dapagliflozin, an experimental Type 2 diabetes drug BMS is developing with AstraZeneca. Dapagliflozin is a new type of drug that prevents blood sugar from being absorbed by the kidneys, thus controlling blood-glucose levels. Study results indicate that patients receiving the drug excreted excess glucose in their urine; the higher the dose of dapagliflozin, the more glucose passed through the patient's system. The drug is currently undergoing larger Phase II trials with results expected later this year. Back in January, AstraZeneca and BMS signed a billion dollar deal to partner up on two diabetes drugs--saxagliptin and dapagliflozin.
- see the release on the data
- read the Wall Street Journal report for more (sub. req.)